Artificial Intelligence

AI Protein Design & Synthetic Biology

Emerging4/5 relationships sourcedProfile verified Aug 14, 2026
OverviewSourcesRelationship mapStoryMilestones

30-Second Executive Brief

Executive Assessment

AI Protein Design & Synthetic Biology functions as an emerging technology within Artificial Intelligence, backed by 70% sourcing coverage, though its relative influence is cooling.

  • Maintains 5 mapped relationships across the graph
  • 70% sourcing coverage across sourced relationships
  • Tracked as emerging technology within the Artificial Intelligence category

Executive Snapshot

Strategic Role
Emerging Technology
Sourcing Coverage
70%
View Methodology →

Computed live from this entity's own relationships and evidence: how many relationships carry at least one linked citation, weighted with citation recency and source type — independent of Strategic Importance, and not a prediction. Not a hand-typed number; recalculated on every read.

Ecosystem Influence
Emerging
Strategic Momentum
Decelerating

Coverage

Mapped Relationships
5
Technology Domains
4

Strategic Implications

  • Central node connecting multiple strategic ecosystems
  • Directly influences technology and capital flows
  • Material relevance to downstream dependency mapping

Top Opportunities

Earendil targeting multiple IND filings in 2026-2027 for its lead antibody programContinued convergence between protein-design AI and traditional AI drug discovery platforms

Top Risks

No AI-designed biologic has yet received full FDA approval, creating validation risk despite large capital inflowsHighly competitive field spanning foundation-model platforms (EvolutionaryScale) and optimization platforms (Cradle) serving overlapping pharma customers

Critical Dependencies

Earendil Labs (Was developed by)Cradle (Was developed by)EvolutionaryScale (Was developed by)
Continue to Dependency Graph ↓

An application of AI foundation models -- protein language models and generative design tools -- to engineer novel proteins, antibodies, and biologics, sitting alongside AI drug discovery as a sibling application of the same techniques applied at the molecular-design level. Beijing/Delaware-based Earendil Labs raised $787 million in March 2026 (backed by Sanofi and a Pfizer/Hillhouse biotech fund) to scale its AI-native biologics platform, which has produced 40+ programs including a Phase 2-ready antibody; Cradle's AI protein engineering platform serves six of the top 25 global pharma companies across 50+ R&D programs; and EvolutionaryScale, founded by former Meta AI researchers, builds ESM3, an open-weight protein language model positioned as a horizontal foundation-model platform for biology.

⚡

Sources

Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.

Evidence

1 source

  • BioSpace / PR Newswire — Earendil Labs raises $787M, Cradle and EvolutionaryScale scale AI protein designnews
⚡

Relationship Map

The relationships surrounding AI Protein Design & Synthetic Biology — ownership, dependencies, regulation, technology and market context. Click any node to make it the new center, 2 levels deep.

2 levels3 levels 🔒5 levels 🔒

Connection type

Sign in free to click a node and explore →

Click any node to make it the new center. Scroll to zoom, drag to pan.

⚡

The Story So Far (last 6 months)

Mar 2026: Earendil Labs raises $787M for AI-driven biologics platform→Mar 2026: Earendil Labs raises $787M, Cradle and EvolutionaryScale scale AI protein design→Aug 2026: Big pharma licensing deals are functioning as the category's real-world validation mechan… (unconfirmed)

Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.

Market Intelligence

Unverified

Credibly-reported claims — analyst notes, sourcing citing “people familiar with the matter,” deals where the companies involved declined to comment — that haven't been officially confirmed. Kept structurally separate from the sourced evidence above; treat as a lead worth researching further, not an established fact.

Big pharma licensing deals are functioning as the category's real-world validation mechanism in the absence of FDA approvals

29% confidence

AI protein design companies have secured substantial pharma validation despite no AI-designed biologic yet reaching full FDA approval: Earendil Labs holds two Sanofi licensing deals worth up to $4.28 billion combined in milestones, while Cradle serves six of the top 25 global pharma companies across 50+ R&D programs.

This is InsightNodes' own interpretive read: with no AI-designed biologic yet fully FDA-approved, the more meaningful near-term validation signal for this category is which platforms established pharma companies are willing to pay real licensing dollars for -- Sanofi's two separate, escalating licensing deals with Earendil (worth up to $4.28 billion combined in milestones) and Cradle's adoption by six of the top 25 global pharma companies both function as a form of expert due diligence by companies with far more biologics development experience than most outside observers, making these commercial relationships a more informative signal than funding size alone.

InsightNodes analysis of pharma validation in AI protein design · Aug 14, 2026

Earendil LabsCradleEvolutionaryScale
⚡

AI Protein Design & Synthetic Biology's Timeline

A sourced, dated history of AI Protein Design & Synthetic Biology's key moments — founding to present.

  1. Mar 2026 · Earendil Labs raises $787M for AI-driven biologics platform

    Earendil Labs raised $787 million in financing, backed by Sanofi and the Pfizer/Hillhouse Biotech Development Fund, to scale its AI-native biologics discovery and development platform, which has already produced more than 40 programs including a Phase 2-ready antibody.